Phase 1 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older who have been diagnosed with an advanced solid tumour that has been confirmed by laboratory testing (pathology).
• People who have at least one measurable tumour that can be tracked using standard imaging measurements (confirm with trial site).
• People whose general health and ability to carry out daily activities meets a specific level of fitness, rated 0 or 1 on a standard oncology scale, with no worsening in the two weeks before starting the trial.
• People with a life expectancy of at least 12 weeks.
• Women who could become pregnant must agree to use effective contraception and must not breastfeed from the time of signing the consent form until 6 months after the last dose.
• Men must agree to use barrier contraception (such as condoms) from signing the consent form until 6 months after the last dose.
• Women who could become pregnant must have a negative pregnancy test within 7 days before the first dose (or have no risk of pregnancy).
• People who are willing to join voluntarily, understand what the study involves, and are able to sign a consent form.

Who may not be able to join:

• People who have previously received or are currently receiving treatments targeting PARP, B7-H4, or B7-H3 (confirm with trial site).
• People who have received certain anti-cancer treatments — including chemotherapy, experimental drugs, anti-tumour traditional Chinese medicines, or other anti-cancer drugs — within 14 days before the first dose, or who would need to continue these during the study.
• People still experiencing side effects rated moderate or worse (Grade 2 or above) from a previous cancer treatment.
• People who have fluid build-up around the lungs or abdomen that requires medical treatment.
• People with a known history of a separate, unrelated cancer.
• People with cancer that has spread to the brain, or cancer affecting the membranes surrounding the brain and spinal cord.
• People whose blood counts, liver function, or kidney function do not meet the required levels (confirm with trial site).
• People with abnormal results on heart tests (confirm with trial site).
• People with serious, uncontrolled, or active heart or cardiovascular conditions.
• People with serious or poorly controlled diabetes.
• People with serious or poorly controlled high blood pressure.
• People who have had significant bleeding or a strong tendency to bleed within the month before the first dose.
• People who have had a serious infection within 4 weeks before the first dose.
• People who have used systemic steroid (glucocorticoid) therapy for more than 7 days within the 28 days before the first dose, or who would need ongoing steroid use during the study, or who have an immune deficiency condition or a history of organ transplantation.
• People with active hepatitis B, hepatitis C, tuberculosis, syphilis, or HIV infection.
• People with current liver-related conditions such as hepatic encephalopathy, hepatorenal syndrome, or moderate-to-severe cirrhosis (confirm with trial site).
• People with moderate or severe lung disease that could interfere with detecting lung-related side effects or that seriously affects breathing.
• People with a history of severe neurological or psychiatric conditions.
• Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
• People who have received a live attenuated vaccine within 4 weeks before the first dose.
• People with an active autoimmune disease, or one that is likely to return.
• People who have had gastrointestinal fistula, a fistula involving internal organs, a hole in the gastrointestinal tract, an abdominal abscess, or signs of bowel obstruction within 6 months before the first dose.
• People who are unlikely to be able to follow the study requirements, as assessed by the trial team.
• People with any other condition that the trial team believes could affect safety or interfere with the study results.

Important: Always verify eligibility with the trial site directly before applying.